Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer

• Published in: Gan to kagaku ryoho Vol. 31; no. 10; p. 1533
• Main Authors: Miyoshi, Kazuya, Ohtsuka, Shinya, Inagaki, Masaru, Ohsaki, Toshihide, Fuchimoto, Sadanori, Yumura, Masahito, Nakagawa, Tomio
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.10.2004
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - chemistry; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Drug Administration Schedule; Female; Floxuridine - administration & dosage; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Nitriles - administration & dosage; Postmenopause; Receptors, Estrogen - analysis; Survival Rate; Triazoles - administration & dosage
• ISSN: 0385-0684

For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice. To enhance the effect of hormonal monotherapy, a combination therapy with Anastrozole 1 mg po and 5'-DFUR 800 mg po daily was given to 11 patients with metastatic breast cancer. At a median follow-up period of 15 months, the overall response rate was 45.5%. The median duration of response in responders was 25 months. The overall median survival for the entire series was 15 months after the start of treatment. No patients complained of adverse events of grade 2 and over. This combination therapy with good response and little side effects is useful for metastatic breast cancer patients.